TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31495886

Group type: EXPERIMENTAL
Intervention: 40% fat intervention
Number of subjects: 10

Group type: COMPARATOR
Intervention: 0% fat intervention
Number of subjects: 10

Group type: COMPARATOR
Intervention: Fasting intervention
Number of subjects: 10
Study: 29239696

Group type: EXPERIMENTAL
Intervention: Low-grade compression garments
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Medium-grade compression garments
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (loose fitting shorts)
Number of subjects: 15
Study: 27917405

Group type: EXPERIMENTAL
Intervention: Sofosbuvir, ledipasvir, and asunaprevir
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Sofosbuvir, daclatasvir, and simeprevir
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Sofosbuvir, daclatasvir, and asunaprevir
Number of subjects: 26
Study: 25085791

Group type: COMPARATOR
Intervention: Expressive suppression (SUPP)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Acceptance (ACC)
Number of subjects: 36
Study: 22094352

Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (TRP‐)
Number of subjects: 18
Study: 19862609

Group type: COMPARATOR
Intervention: Erythropoiesis stimulating agents (ESA) therapy
Number of subjects: 663
Study: 18067807

Group type: EXPERIMENTAL
Intervention: Propofol preconditioning (2 mg/kg pre-operatively and 5 mg.kg(‐1).h(‐1) intra-operatively)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (midazolam 0.2 mg/kg pre‐ and 0.1 mg.kg(‐1).h(‐1) intra-operatively)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Propofol preconditioning
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 15187831

Group type: EXPERIMENTAL
Intervention: Crystalloid solutions as initial volume expanders
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blood and blood products
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Massive resuscitations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Novel blood substitutes and hypertonic saline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Minimally invasive hemodynamic monitoring techniques
Number of subjects: 0
Study: 11774289

Group type: EXPERIMENTAL
Intervention: L-cysteine-containing tablet
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo tablet
Number of subjects: 9
Study: 10430253

Group type: EXPERIMENTAL
Intervention: Mammographic screening
Number of subjects: 77080

Group type: COMPARATOR
Intervention: No invitation to mammographic screening (Control)
Number of subjects: 77080
Study: 8643970

Group type: EXPERIMENTAL
Intervention: 1-hour infusion of paclitaxel at 135 mg/m2
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: 1-hour infusion of paclitaxel combined with cisplatin/etoposide plus radiation therapy
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: 1-hour infusion of paclitaxel combined with carboplatin and extended-schedule etoposide
Number of subjects: 59
Study: 2106783

Group type: EXPERIMENTAL
Intervention: rt‐PA alone
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: rt‐PA plus heparin
Number of subjects: 64

Group type: COMPARATOR
Intervention: heparin alone
Number of subjects: 64
Study: 108738

Group type: EXPERIMENTAL
Intervention: Active marijuana containing 6 mg delta 9‐THC
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 30468772

Group type: EXPERIMENTAL
Intervention: Continuity Care Intensivist (CCI) intervention
Number of subjects: 0
Study: 29557090

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 2719

Group type: COMPARATOR
Intervention: Standard prophylaxis (enoxaparin)
Number of subjects: 2719
Study: 25433985

Group type: EXPERIMENTAL
Intervention: Low fidelity (part task trainer only)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Medium fidelity (part task trainer and life sized poster of a pregnant woman)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Progressive fidelity (part task trainer and a simulated standardised patient)
Number of subjects: 69
Study: 24118450

Group type: EXPERIMENTAL
Intervention: Generic tacrolimus (Sandoz)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Reference tacrolimus
Number of subjects: 68
Study: 21196865

Group type: EXPERIMENTAL
Intervention: Hypoclean
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Tetraclean
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 5.25% sodium hypochlorite (NaOCl)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Infected dentin tubes (positive control)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Sterile dentin tubes (negative control)
Number of subjects: 90
Study: 18957505

Group type: EXPERIMENTAL
Intervention: Vildagliptin (50 mg twice daily)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 17585011

Group type: EXPERIMENTAL
Intervention: Bivalent P. aeruginosa flagella vaccine
Number of subjects: 483

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 483
Study: 15252415

Group type: EXPERIMENTAL
Intervention: Tailored message intervention during hospitalization and 1 week and 1 month after discharge
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Tailored message intervention
Number of subjects: 70
Study: 15317827

Group type: EXPERIMENTAL
Intervention: Intravenous (IV) rHuEpo, single doses ranging from 10 to 500 IU/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subcutaneous (SC) rHuEpo, single doses ranging from 300 to 2400 IU/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subcutaneous (SC) rHuEpo, multiple doses of 150 IU/kg/3 times a week and 600 IU/kg/week
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 10510148

Group type: EXPERIMENTAL
Intervention: Zaleplon 10 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 7497561

Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg intravenously
Number of subjects: 80

Group type: COMPARATOR
Intervention: Ranitidine 50 mg intravenously
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study: 1742538

Group type: EXPERIMENTAL
Intervention: Rifaximine
Number of subjects: 14

Group type: COMPARATOR
Intervention: Neomycin
Number of subjects: 14
Study: 7092330

Group type: EXPERIMENTAL
Intervention: Sulfuric acid (H2SO4) exposure (average 108 micrograms/m3 for 4 hours)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Clean air exposure (control group)
Number of subjects: 35
Study: 30609428

Group type: EXPERIMENTAL
Intervention: Distraction with music and video games via iPod (n = 109)
Number of subjects: 219

Group type: COMPARATOR
Intervention: No iPod (control group, n = 110)
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Distraction with music and video games via iPod
Number of subjects: 219
Study: 28799197

Group type: EXPERIMENTAL
Intervention: Family Nurse Partnership (FNP) intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 25739527

Group type: EXPERIMENTAL
Intervention: Rehabilitation group (n = 134)
Number of subjects: 234

Group type: COMPARATOR
Intervention: Control group (n = 100)
Number of subjects: 234
Study: 23715718

Group type: EXPERIMENTAL
Intervention: Finding scientific problems with related heuristic knowledge
Number of subjects: 76

Group type: COMPARATOR
Intervention: Finding conventional problems without related heuristic knowledge
Number of subjects: 76
Study: 21247665

Group type: EXPERIMENTAL
Intervention: Aquaphor Healing Ointment (AHO)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Poly/Bac/Neo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Poly/Bac
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (untreated wound)
Number of subjects: 20
Study: 19570236

Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy (CBT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intensified treatment as usual (TAU)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Guided self-help group intervention (SH)
Number of subjects: 0
Study: 17166799

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (higher dose)
Number of subjects: 499

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (lower dose)
Number of subjects: 499

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 499
Study: 15132726

Group type: EXPERIMENTAL
Intervention: Pulsatile intravenous GnRH (5 microg every 90 min for 36 hours)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Single dose GnRH-agonist stimulation test (buserelin acetate, 10 microg/kg body weight)
Number of subjects: 19
Study: 11478009

Group type: EXPERIMENTAL
Intervention: Needlescopic cholecystectomy (NC)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Conventional laparoscopic cholecystectomy (LC)
Number of subjects: 64
Study: 9736567

Group type: EXPERIMENTAL
Intervention: 3 mg/kg/day PMPA
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 1 mg/kg/day PMPA
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 8070432

Group type: EXPERIMENTAL
Intervention: Ampicillin/sulbactam
Number of subjects: 75

Group type: COMPARATOR
Intervention: Cefamandole
Number of subjects: 75
Study: 31976596

Group type: EXPERIMENTAL
Intervention: RNA interference targeting HPV16 E6/E7 gene
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: p16INK4a gene
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: hTERC gene
Number of subjects: 226

Group type: COMPARATOR
Intervention: p16INK4a, Notch1, and hTERC genes
Number of subjects: 226
Study: 29998809

Group type: EXPERIMENTAL
Intervention: Silicone tube intubation and tube stenting (Group 1)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Silicone tube intubation only (Group 2)
Number of subjects: 70
Study: 27740930

Group type: COMPARATOR
Intervention: Normal glucose tolerance (NGT)
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Impaired glucose tolerance (IGT)
Number of subjects: 177

Group type: COMPARATOR
Intervention: NGT-hyperinsulinemia (NGT-HI)
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Overall glucose metabolism alterations
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: HOMA-IR levels
Number of subjects: 177
Study: 25168278

Group type: EXPERIMENTAL
Intervention: High-dose atorvastatin loading (80 mg for 3 days, followed by 10 mg/day until discharge)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No statin therapy
Number of subjects: 0
Study: 23558602

Group type: EXPERIMENTAL
Intervention: Compound omeprazole capsule (40 mg)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Delayed-release omeprazole (40 mg)
Number of subjects: 42
Study: 20513826

Group type: EXPERIMENTAL
Intervention: Group Medical Clinics (GMC)
Number of subjects: 239

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 239
Study: 18715125

Group type: EXPERIMENTAL
Intervention: Water + electrolyte solution
Number of subjects: 16

Group type: COMPARATOR
Intervention: Plain water
Number of subjects: 16
Study: 16790114

Group type: EXPERIMENTAL
Intervention: Conservative ovarian surgery (Group I)
Number of subjects: 99

Group type: COMPARATOR
Intervention: ICSI cycle directly (Group II)
Number of subjects: 99
Study: 14644891

Group type: EXPERIMENTAL
Intervention: Oral anticoagulant therapy for at least 3 months
Number of subjects: 4374

Group type: EXPERIMENTAL
Intervention: Oral anticoagulant therapy for more than 3 months
Number of subjects: 4374
Study: 10730732

Group type: EXPERIMENTAL
Intervention: 0.25 mg x kg(‐1) mivacurium
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 0.6 mg x kg(‐1) rocuronium
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 0.08 mg kg(‐1) mivacurium plus 0.2 mg x kg(‐1) rocuronium
Number of subjects: 90
Study: 9179543

Group type: EXPERIMENTAL
Intervention: Calcium infusion
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 8247075

Group type: EXPERIMENTAL
Intervention: Immune globulin (2 g per kilogram of body weight)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Immune globulin (after crossover)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Immune globulin (biopsies)
Number of subjects: 15
Study: 3102089

Group type: EXPERIMENTAL
Intervention: Ifosfamide (IFOS) 5 g/m2
Number of subjects: 171

Group type: COMPARATOR
Intervention: Cyclophosphamide (CYCLO) 1.5 g/m2
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Ifosfamide (IFOS)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Cyclophosphamide (CYCLO)
Number of subjects: 171
Study: 30641301

Group type: EXPERIMENTAL
Intervention: Early pubertal onset
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Early pubertal onset with a sexual partner more than 2 years older
Number of subjects: 121
Study: 27759623

Group type: EXPERIMENTAL
Intervention: 2-day antimicrobial prophylaxis (antibiotic treatment on days 1 and 2)
Number of subjects: 86

Group type: COMPARATOR
Intervention: 4-day antimicrobial prophylaxis (antibiotic treatment on days 1 to 4)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: 2-day antimicrobial prophylaxis
Number of subjects: 86

Group type: COMPARATOR
Intervention: 4-day antimicrobial prophylaxis
Number of subjects: 86
Study: 26956650

Group type: EXPERIMENTAL
Intervention: Stepped care (psychoeducation, guided Internet treatment, and face-to-face CBT)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Direct face-to-face CBT
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Stepped care
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 173
Study: 25409776

Group type: EXPERIMENTAL
Intervention: Collaborative care intervention (behavioural activation and medication management) delivered over eight to 10 weekly sessions by a case manager liaising with general practitioners.
Number of subjects: 450

Group type: COMPARATOR
Intervention: Usual GP care (control group).
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Collaborative care intervention (cost effectiveness analysis).
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Collaborative care intervention (qualitative process evaluation).
Number of subjects: 450
Study: 21933332

Group type: EXPERIMENTAL
Intervention: Home uroflowmetry
Number of subjects: 186

Group type: COMPARATOR
Intervention: IPSS
Number of subjects: 186
Study: 20215619

Group type: EXPERIMENTAL
Intervention: efavirenz, lamivudine and enteric-coated didanosine (efavirenz-A [QD])
Number of subjects: 262

Group type: COMPARATOR
Intervention: efavirenz plus continuation of current nucleoside reverse transcriptase inhibitors (efavirenz-B)
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Both regimens (efavirenz-A and efavirenz-B)
Number of subjects: 262
Study: 18566298

Group type: EXPERIMENTAL
Intervention: Extended-release niacin (2 g/d)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Extended-release niacin (2 g/d) plus lovastatin (40 mg/d)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 15944165

Group type: EXPERIMENTAL
Intervention: Behavioral Intervention (BI), N = 25
Number of subjects: 49

Group type: COMPARATOR
Intervention: Enhanced Standard of Care (ESC), N = 24
Number of subjects: 49
Study: 11996927

Group type: EXPERIMENTAL
Intervention: 100 mg androstenedione
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: 300 mg androstenedione
Number of subjects: 37

Group type: COMPARATOR
Intervention: 0 mg androstenedione (control group)
Number of subjects: 37
Study: 10102588

Group type: EXPERIMENTAL
Intervention: 30% N2O with clonidine
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: 30% N2O
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: 100% oxygen with clonidine
Number of subjects: 33

Group type: COMPARATOR
Intervention: 100% oxygen with placebo
Number of subjects: 33

Group type: COMPARATOR
Intervention: 30% N2O with placebo
Number of subjects: 33
Study: 8830642

Group type: EXPERIMENTAL
Intervention: Metamphocin (methyl ether of amphotericin B) administered as drop-like intravenous injections in combination with local instillation of ketoconazole and dexamethasone.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Metamphocin (methyl ether of amphotericin B)
Number of subjects: 10
Study: 1969678

Group type: EXPERIMENTAL
Intervention: Liquid defined formula diet (DFD)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Combination of 6‐methyl‐prednisolone and sulfasalazine (drug treatment)
Number of subjects: 95
Study: 376208

Group type: EXPERIMENTAL
Intervention: Fenoterol 0.25 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Fenoterol 2.5 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31651927

Group type: EXPERIMENTAL
Intervention: Aquatic Exercise (AE)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Land Exercise (LE)
Number of subjects: 40
Study: 30728886

Group type: EXPERIMENTAL
Intervention: Docosahexaenoic Acid (DHA) at 100 μM for 48 hours
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Melatonin (MLT) at 1 μM for 48 hours
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Coincubation of DHA and MLT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DHA isolated
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Melatonin (MLT) alone or coincubated with DHA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All incubations (DHA, MLT, and coincubation)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Melatonin (MLT)
Number of subjects: 0
Study: 27988287

Group type: EXPERIMENTAL
Intervention: Multiple biopsy specimens
Number of subjects: 57

Group type: COMPARATOR
Intervention: Forceps biopsy specimens
Number of subjects: 57
Study: 27122516

Group type: EXPERIMENTAL
Intervention: Single blade technique
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Double blade technique
Number of subjects: 184

Group type: COMPARATOR
Intervention: Control blades (not specified as intervention)
Number of subjects: 184
Study: 24646068

Group type: EXPERIMENTAL
Intervention: IV-ibuprofen (10 mg·kg(‐1))
Number of subjects: 161

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 161
Study: 21674629

Group type: EXPERIMENTAL
Intervention: Optimized botanical combination containing policosanol, tomato extract, orally bioavailable grape procyanidins and Oenothera biennis oil
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 19254446

Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Treatment-as-usual waitlist control
Number of subjects: 68
Study: 17594627

Group type: EXPERIMENTAL
Intervention: Vitrectomy
Number of subjects: 33
Study: 15802314

Group type: EXPERIMENTAL
Intervention: Circular excision and subsequent stripping
Number of subjects: 48

Group type: COMPARATOR
Intervention: Direct stripping
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Stripping at the hilus
Number of subjects: 48

Group type: COMPARATOR
Intervention: Coagulation and cutting at the hilus
Number of subjects: 48
Study: 12225709

Group type: EXPERIMENTAL
Intervention: Late intervention and stent to the LAD + medical therapy (open artery group)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Medical therapy (closed artery group)
Number of subjects: 66
Study: 9606690

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (i.v.Ig) administered monthly at a dosage of 0.15‐0.20 g/kg for 2 years
Number of subjects: 148

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study: 7624465

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group therapy (CBT; n = 14)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Experiential group therapy program (ET; n = 12)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Comparison group of 149 HIV-infected men
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Both interventions (CBT and ET)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Subjects showing larger decreases in distress
Number of subjects: 26
Study: 2243877

Group type: EXPERIMENTAL
Intervention: Flurbiprofen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Flurbiprofen plus alprazolam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Flurbiprofen plus placebo
Number of subjects: 0
Study: 541683

Group type: EXPERIMENTAL
Intervention: Inactivated hepatitis B vaccine
Number of subjects: 3000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3000
Study: 29148597

Group type: EXPERIMENTAL
Intervention: Collagenated bovine-derived bone (DBBM-C) covered with a collagen membrane
Number of subjects: 30

Group type: COMPARATOR
Intervention: Spontaneous healing (control group)
Number of subjects: 30
Study: 26257143

Group type: EXPERIMENTAL
Intervention: Vaporized cannabis (2.9% and 6.7% THC)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Concurrent low-dose alcohol (0.065g/210L peak BrAC)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Vaporized cannabis
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Oral fluid (OF) testing
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Blood THC concentrations
Number of subjects: 19
Study: 24721888

Group type: EXPERIMENTAL
Intervention: Low-dose rapamycin (LD)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Standard-dose rapamycin (STD)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Combined treatment groups (LD+STD)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 30
Study: 22397390

Group type: EXPERIMENTAL
Intervention: Music therapy
Number of subjects: 76

Group type: COMPARATOR
Intervention: Standard rehabilitation
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Both groups (music therapy and standard rehabilitation)
Number of subjects: 76
Study: 20134405

Group type: EXPERIMENTAL
Intervention: Korean red ginseng (KRG) root 3 g
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Ginsenoside fraction 3 g
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Polysaccharide fraction 3 g
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo 3 g
Number of subjects: 17
Study: 18751561

Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (TMS)
Number of subjects: 4
Study: 15973097

Group type: EXPERIMENTAL
Intervention: Laparoscopic Roux-en-Y gastric bypass (LRYGBP)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Laparoscopic mini-gastric bypass (LMGBP)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 80
Study: 12735487

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Psychiatric drugs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Symbolic meaning hypothesis
Number of subjects: 0